InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids

InMed Pharmaceuticals完成对BayMedica的收购,成为稀有大麻素制造领域的市场领导者

2021-10-14 10:00:06 BioSpace

本文共2224个字,阅读需6分钟

VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2021 -- InMed Pharmaceuticals Inc. , a leader in the manufacturing and clinical development of rare cannabinoids, today announced that they have completed the previously announced acquisition of BayMedica Inc. , a private company based in the US specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector. Eric A. Adams, President and Chief Executive Officer of InMed, stated, “We are delighted to close this acquisition and welcome everyone at BayMedica to the InMed team. In the next several weeks, we will focus on corporate integration, exploring our combined manufacturing know-how and looking to accelerate revenue growth. BayMedica brings significant expertise and will help strengthen our pharmaceutical drug development efforts as well as position the Company to become a global leader in the manufacturing of rare cannabinoids.” Shane Johnson, Senior Vice President and General Manager of BayMedica, stated, “We are very pleased to finalize this transaction and join forces with InMed. Together we have the capabilities and resources to accelerate our commercial initiatives and expedite the launch of several new cannabinoids products in the consumer health and wellness sector. The combined technologies in rare cannabinoid manufacturing, including synthetic biology, chemical synthesis and enzymatic biotransformation (IntegraSyn™), establishes us as a leader in the field.” Acquisition overview and amended transaction terms: InMed acquired 100% of BayMedica in exchange for 2.05 million InMed common shares issued to BayMedica’s equity and convertible debt holders, subject to a six-month contractual hold period. The previously announced issuance of Series A and Series B warrants to acquire 1.6 million common shares was replaced with a cash component of US$1 million. The entirety of this cash consideration will be held in escrow, subject to cancellation, to satisfy certain potential post-closing indemnification and other claims that InMed may have under the definitive agreement in the six- and twelve-month periods following the closing. To learn more about the transaction and hear more about InMed’s future developments, please visit our website and view a recent webinar featuring Eric A. Adams and Shane Johnson. About InMed: InMed Pharmaceuticals is a global leader in the manufacturing and development of rare cannabinoids. Together with our subsidiary, BayMedica, we have unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. We are a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com. About BayMedica: BayMedica Inc. is a revenue-stage biotechnology company leveraging synthetic biology and pharmaceutical chemistry to develop an efficient, scalable, and proprietary platform to produce high quality, rare cannabinoids for consumer applications and cannabinoid-derived new chemical entities for pharmaceutical applications. For more information, visit www.baymedica.com. Investor Contact: Colin Clancy Senior Director, Investor Relations T: +1 604 416 0999 E: cclancy@inmedpharma.com Edison Group: Joe Green/Laine Yonker T:   +1.646.653.7030/+1.646.653.7035 E: jgreen@edisongroup.com / lyonker@edisongroup.com Cautionary Note Regarding Forward-Looking Information: This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “potential”, “possible”, “would” and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: BayMedica’s plans for further product launches; the results and potential benefits of the combination of InMed and BayMedica’s business models and their future growth potential. With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: the anticipated results and potential of BayMedica’s business and the combination of BayMedica’s business with InMed’s business occurring; continued economic and market stability; delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs; advancing IntegraSyn™ to commercial scale production; IntegraSyn™ being a commercially viable solution for large-scale, pharmaceutical-grade GMP production of rare cannabinoids; and developing a pipeline of cannabinoid-based pharmaceutical drug candidates. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: regulatory filings may not be filed or approved on a timely basis, or at all. A more complete discussion of the risks and uncertainties facing InMed’s stand-alone business is disclosed in InMed’s Annual Report on Form 10-K and other filings with the Security and Exchange Commission on www.sec.gov and the most recent Annual Information Form and other continuous disclosure filed with Canadian securities regulatory authorities on SEDAR at www.sedar.com. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
2021年10月13日(环球新闻)--稀有大麻素制造和临床开发的领导者InMed Pharmaceuticals Inc.(“InMed”或“公司”)(纳斯达克代码:INM)今天宣布,他们已经完成了此前宣布的对BayMedica Inc.(“BayMedica”)的收购,BayMedica是一家总部位于美国的私营公司,专门为健康和健康部门制造和商业化稀有大麻素。 InMed总裁兼首席执行官Eric A.Adams表示:“我们很高兴完成这次收购,并欢迎BayMedica的每一个人加入InMed团队。在接下来的几周里,我们将专注于公司整合,探索我们的联合制造技术,并寻求加快收入增长。BayMedica带来了重要的专业知识,将有助于加强我们的药物开发努力,并使该公司成为稀有大麻素制造的全球领导者。“ BayMedica公司高级副总裁兼总经理Shane Johnson表示:“我们非常高兴能与INMED公司达成交易并联手。我们有能力和资源一起加快我们的商业举措,并在消费者健康和保健部门加快推出几种新的大麻素产品。稀有大麻素制造的联合技术,包括合成生物学、化学合成和酶生物转化(™Integrasyn),使我们成为该领域的领导者。“ 收购概况及经修订的交易条款:InMed收购BayMedica 100%的股份,以换取205万股InMed普通股发行给BayMedica的股权及可转换债务持有人,但合约持有期为6个月。此前宣布发行A系列和B系列认股权证以收购160万股普通股的做法被美国100万美元的现金部分取代。该现金代价的全部将以代管方式持有,但须予取消,以满足InMed根据最终协议在交割后六个月及十二个月期间可能拥有的若干潜在交割后弥偿及其他申索。 要了解更多关于交易和听到更多关于INMED的未来发展,请访问我们的网站,并查看最近的网络研讨会埃里克a亚当斯和谢恩约翰逊。 关于InMed:InMed制药公司是稀有大麻素制造和开发的全球领导者。与我们的子公司BayMedica一起,我们拥有无与伦比的大麻素制造能力,为一系列消费者市场服务,包括制药和健康和健康。我们是一家临床阶段的公司,开发一系列稀有大麻素疗法,并致力于向可能受益于大麻素类药物的患者提供新的治疗替代方案。欲了解更多信息,请访问www.inmedpharma.com。 关于BayMedica:BayMedica Inc.是一家盈利阶段的生物技术公司,利用合成生物学和药物化学开发一个免费的、可扩展的和专有的平台,为消费者应用生产高质量的稀有大麻素,并为制药应用生产大麻素衍生的新化学实体。欲了解更多信息,请访问www.baymedica.com。 投资者联系方式: 科林·克兰西 投资者关系高级总监 T:+1 604 416 099 9 E:cclancy@inmedpharma.com 爱迪生集团: 乔·格林/莱恩·扬克 T:+1.646.653.7030/+1.646.653.7035 电子:jgreen@edisongroup.com/lyonker@edisongroup.com 关于前瞻性信息的警告: 本新闻稿包含适用证券法所指的“前瞻性信息”和“前瞻性陈述”(统称为“前瞻性信息”)。前瞻性陈述经常但并非总是用诸如“预期”、“预期”、“相信”、“打算”、“潜在”、“可能”、“将”等词和类似的表达方式来识别。这些陈述基于管理层目前的预期,内在地涉及许多已知和未知的风险、不确定性和假设,其中许多是我们无法控制的。前瞻性信息是基于管理层目前的预期和信念,并受到一些风险和不确定性的影响,这些风险和不确定性可能导致实际结果与前瞻性陈述中描述的结果存在重大差异。本新闻稿中的前瞻性信息包括以下声明:Baymedica计划进一步推出产品;InMed和Baymedica业务模式结合的结果和潜在利益及其未来增长潜力。 关于本新闻稿中包含的前瞻性信息,InMed已就以下事项作出了许多假设:Baymedica业务的预期结果和潜力以及Baymedica业务与InMed业务的合并;经济和市场持续稳定;向可能受益于大麻素类药物的患者提供新的治疗替代方案;将Integrasyn™公司推向商业规模生产;Integrasyn™公司是一个商业上可行的解决方案,用于稀有大麻素的大规模、制药级GMP生产;并开发了一系列以大麻素为基础的候选药物。虽然InMed认为这些假设是合理的,但这些假设本质上受制于重大的商业、经济、竞争、市场和社会不确定性和或有事项。 此外,存在已知和未知的风险因素,可能导致INMED的实际结果、业绩或成就与本报告所载前瞻性信息所表达或暗示的任何未来结果、业绩或成就有重大差异。已知的风险因素除其他外包括:监管备案可能无法及时提交或批准,或者根本无法及时提交或批准。关于INMED独立业务面临的风险和不确定性的更完整的讨论,在INMED向证券交易委员会提交的10-K表和其他文件(www.sec.gov)以及向加拿大证券监管当局提交的关于SEDAR的最新年度信息表和其他持续披露(www.SEDAR.com)中披露。 本警示声明对本报告中的所有前瞻性信息进行了全面的限定,InMed不承担任何义务修改或更新任何此类前瞻性信息,或公开宣布对本报告中所包含的任何前瞻性信息的任何修改的结果,以反映未来的结果、事件或发展,除非法律有要求。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文